Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner.
Animals
Apoptosis
Biomarkers, Tumor
/ genetics
Bone Marrow Cells
/ metabolism
Bone Neoplasms
/ genetics
Cell Communication
Cell Proliferation
Cholesterol
/ metabolism
Extracellular Vesicles
/ genetics
Gene Expression Profiling
Humans
Male
Mice
Mice, Inbred C57BL
Mice, SCID
Prostatic Neoplasms
/ genetics
Signal Transduction
Tumor Cells, Cultured
Tumor Microenvironment
Xenograft Model Antitumor Assays
bone
cholesterol
exosomes
extracellular vesicles
metastasis
myeloid
pre‐metastatic niche
prostate cancer
Journal
Journal of extracellular vesicles
ISSN: 2001-3078
Titre abrégé: J Extracell Vesicles
Pays: United States
ID NLM: 101610479
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
10
06
2020
revised:
10
11
2020
accepted:
28
11
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
ppublish
Résumé
Primary tumours can establish long-range communication with distant organs to transform them into fertile soil for circulating tumour cells to implant and proliferate, a process called pre-metastatic niche (PMN) formation. Tumour-derived extracellular vesicles (EV) are potent mediators of PMN formation due to their diverse complement of pro-malignant molecular cargo and their propensity to target specific cell types (Costa-Silva et al., 2015; Hoshino et al., 2015; Peinado et al., 2012; Peinado et al., 2017). While significant progress has been made to understand the mechanisms by which pro-metastatic EVs create tumour-favouring microenvironments at pre-metastatic organ sites, comparatively little attention has been paid to the factors intrinsic to recipient cells that may modify the extent to which pro-metastatic EV signalling is received and transduced. Here, we investigated the role of recipient cell cholesterol homeostasis in prostate cancer (PCa) EV-mediated signalling and metastasis. Using a bone metastatic model of enzalutamide-resistant PCa, we first characterized an axis of EV-mediated communication between PCa cells and bone marrow that is marked by in vitro and in vivo PCa EV uptake by bone marrow myeloid cells, activation of NF-κB signalling, enhanced osteoclast differentiation, and reduced myeloid thrombospondin-1 expression. We then employed a targeted, biomimetic approach to reduce myeloid cell cholesterol in vitro and in vivo prior to conditioning with PCa EVs. Reducing myeloid cell cholesterol prevented the uptake of PCa EVs by recipient myeloid cells, abolished NF-κB activity and osteoclast differentiation, stabilized thrombospondin-1 expression, and reduced metastatic burden by 77%. These results demonstrate that cholesterol homeostasis in bone marrow myeloid cells regulates pro-metastatic EV signalling and metastasis by acting as a gatekeeper for EV signal transduction.
Identifiants
pubmed: 33408816
doi: 10.1002/jev2.12042
pii: JEV212042
pmc: PMC7775568
doi:
Substances chimiques
Biomarkers, Tumor
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e12042Subventions
Organisme : NIAMS NIH HHS
ID : T32 AR060710
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA186897
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM105538
Pays : United States
Informations de copyright
© 2020 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2511-6
pubmed: 23345442
EMBO J. 2010 Aug 18;29(16):2677-88
pubmed: 20717138
Clin Cancer Res. 2008 Aug 15;14(16):5013-21
pubmed: 18698019
Lancet. 2012 Jan 7;379(9810):39-46
pubmed: 22093187
Sci Rep. 2015 Oct 29;5:15724
pubmed: 26511855
Hum Pathol. 2000 May;31(5):578-83
pubmed: 10836297
J Biol Chem. 2013 Jun 14;288(24):17713-24
pubmed: 23653359
J Exp Med. 2019 Dec 2;216(12):2883-2899
pubmed: 31548301
Biochemistry. 2012 Jan 10;51(1):90-9
pubmed: 22142403
J Biol Chem. 2016 Feb 12;291(7):3439-54
pubmed: 26670608
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394
Trends Cell Biol. 2017 Mar;27(3):172-188
pubmed: 27979573
Methods Mol Biol. 2012;816:187-202
pubmed: 22130930
Cancer Discov. 2013 May;3(5):578-89
pubmed: 23633432
Traffic. 2018 Oct;19(10):750-760
pubmed: 29896788
Sci Rep. 2014 Jul 18;4:5750
pubmed: 25034888
Oncotarget. 2016 May 3;7(18):26259-74
pubmed: 27036029
Subcell Biochem. 2010;51:439-66
pubmed: 20213554
Cancer Res. 2019 Jun 15;79(12):3063-3075
pubmed: 30987997
Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):1-12
pubmed: 26708594
Cancer Cell. 2012 Feb 14;21(2):181-95
pubmed: 22340592
Bonekey Rep. 2015 May 20;4:689
pubmed: 26029360
Subcell Biochem. 2010;51:183-227
pubmed: 20213545
J Cell Biol. 1991 Nov;115(4):1127-36
pubmed: 1720121
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13
pubmed: 19887582
Oncogene. 2017 Nov 16;36(46):6462-6471
pubmed: 28759039
J Clin Invest. 2002 Sep;110(5):597-603
pubmed: 12208858
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
Nat Commun. 2012;3:1249
pubmed: 23212378
J Bone Miner Res. 2013 May;28(5):1203-13
pubmed: 23165930
Cancer Res. 2017 Apr 1;77(7):1662-1673
pubmed: 28130224
J Mol Biol. 2005 Jan 14;345(2):339-50
pubmed: 15571726
J Immunol. 2011 Aug 15;187(4):1529-35
pubmed: 21810617
PLoS One. 2010 Jun 17;5(6):e11162
pubmed: 20567600
Mol Cancer Ther. 2018 Mar;17(3):686-697
pubmed: 29282300
Crit Rev Eukaryot Gene Expr. 2009;19(2):109-24
pubmed: 19392647
J Immunol. 2007 Jun 1;178(11):6867-75
pubmed: 17513735
Curr Mol Med. 2013 May;13(4):626-39
pubmed: 23061677
Int Rev Cell Mol Biol. 2010;282:135-63
pubmed: 20630468
Semin Cell Dev Biol. 2017 Jul;67:3-10
pubmed: 28077297
ACS Appl Mater Interfaces. 2018 Feb 28;10(8):6904-6916
pubmed: 29385802
Cold Spring Harb Symp Quant Biol. 2016;81:151-161
pubmed: 28381439
Expert Rev Anticancer Ther. 2019 Jun;19(6):515-528
pubmed: 31148521
Cancer Causes Control. 2011 Jul;22(7):1011-9
pubmed: 21562751
J Cell Biochem. 2004 Mar 1;91(4):718-29
pubmed: 14991763
Asian J Urol. 2016 Oct;3(4):229-239
pubmed: 29264191
Front Endocrinol (Lausanne). 2018 Nov 28;9:694
pubmed: 30546345
Int J Cancer. 2008 Oct 1;123(7):1693-8
pubmed: 18646186
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2213-7
pubmed: 17971518
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
PLoS One. 2008;3(11):e3627
pubmed: 18978943
Nat Commun. 2017 Nov 6;8(1):1319
pubmed: 29105655
Cancer Res. 2012 Mar 15;72(6):1384-94
pubmed: 22282653
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Cancer Causes Control. 2010 Jan;21(1):61-8
pubmed: 19806465
J Cell Biol. 1989 Sep;109(3):1309-19
pubmed: 2768342
PLoS One. 2010 Dec 03;5(12):e14175
pubmed: 21151972